At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, reviews the development of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) signalling pathway and the identification of predictive biomarkers of response to immunotherapies for the management of patients with lung cancer.
Immune checkpoint inhibitors and biomarker-driven strategies for managing lung cancer
26th August 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now